Accordingly, encouraging results come from the combination of ICIs and HER2-targeted trastuzumab emtansine in the treatment of PD-L1+, HER2+ advanced breast cancer (Emens et al., 2020). The gene discussed is ERBB2; the disease is breast carcinoma.